Rehfeldt C, Renne U, Sawitzky M, Binder G, Hoeflich A. Increased fat mass, decreased myofiber size, and a shift to glycolytic muscle metabolism in adolescent male transgenic mice overexpressing IGFBP-2. Am J Physiol Endocrinol Metab 299: E287-E298, 2010. First published May 25, 2010; doi:10.1152/ajpendo.00492.2009.-To elucidate the functional role of insulin-like growth factor (IGF)-binding protein-2 (IGFBP-2) for in vivo skeletal muscle growth and function, skeletal muscle cellularity and metabolism, expression of signal molecules, and body growth and composition were studied in a transgenic mouse model overexpressing IGFBP-2. Postnatal growth rate of transgenic mice was reduced from day 21 of age by 6 -8% compared with nontransgenic controls. At 10 wk of age body lean protein and moisture percentages were lower, whereas fat percentage was higher in IGFBP-2 transgenic mice. Muscle weights were reduced (Ϫ13% on day 30 of age, Ϫ14% on day 72), which resulted from slower growth of myofibers in size but not from decreases in myofiber number. The reduction in muscle mass was associated with lower total DNA, RNA, and protein contents as well as greater DNA/RNA and protein/RNA ratios. The percentage of proliferating (Ki-67-positive) nuclei within myofibers was reduced (3.4 vs. 5.8%) in 30-day-old transgenic mice. These changes were accompanied by slight reductions in specific p44/42 MAPK activity (Ϫ18% on day 72) and, surprisingly, by increased levels of phosphorylated Akt (Ser 473 ) (ϩ25% on day 30, ϩ66% on day 72). The proportion of white glycolytic fibers (55.9 vs. 53.5%) and the activity of lactate dehydrogenase (ϩ8%) were elevated in 72-day-old transgenic mice. Most of the differences observed between transgenic and nontransgenic mice were more pronounced in males. The results suggest that IGFBP-2 significantly inhibits postnatal skeletal myofiber growth by decreasing myogenic proliferation and protein accretion and enhances glycolytic muscle metabolism.
IT IS COMMONLY RECOGNIZED that the insulin-like growth factor (IGF) system plays an important role in myogenesis and postnatal muscle growth (14, 32, 39) . IGF-I and IGF-II stimulate both myoblast proliferation and differentiation in temporally separated periods of myogenesis via specific signaling pathways by endocrine or autocrine/paracrine mechanisms (14, 39) . In the absence of IGF-I receptor signaling, mice die perinatally with severe muscle hypoplasia and respiratory failure due to muscular weakness (27) . The actions of the IGFs are modulated by a family of six IGF-binding proteins (IGFBP), designated as IGFBP-1 to -6 (25) . IGFBPs may protect the IGFs against degradation; they are able to potentate or inhibit the biological actions of the IGFs and may also have IGFindependent actions (4) . IGFBPs regulate growth and development by regulating IGF transport to tissues and IGF bioavailability to IGF receptors at the cell membrane level. IGFBP excess leads predominantly to inhibition of IGF action and growth retardation with impaired organogenesis (51, 60) .
It is known that muscle cell cultures produce various amounts of IGFs and IGFBPs, depending on the origin (species and muscle type) and developmental stage of the cells (12, 18, 24) . From in vitro studies it has been concluded that the IGFBPs have the potential to affect muscle cell growth during critical periods of development and to impact ultimate muscle mass in the postnatal period (13, 33, 36) . The production and secretion of IGFBPs is under the control of IGFs and other growth factors, such as basic fibroblast growth factor and transforming growth factor-␤ (18, 63) . However, the specific effects of elevated IGFBPs for muscle development and growth in vivo have received only a limited number of functional studies, although transgenic mouse models systemically overexpressing IGFBP-1 to -5 all exhibited inhibitory phenotypes for muscle growth or metabolism (21, 41, 47, 50, 56) . Importantly, the carcass, which is composed mainly of muscle tissue, has been identified as the main target for the inhibitory effects of IGFBP-2 in transgenic mice (21) . IGFBP-2 levels are also of critical importance for humans since high serum IGFBP-2 concentrations were correlated with lower lean mass and lower muscle strength but higher degrees of disability in elderly men (55). To define the effects of higher IGFBP-2 expression on muscle growth and metabolism, we have examined cellular properties of skeletal muscle by means of histological and biochemical analyses in IGFBP-2 transgenic mice.
MATERIALS AND METHODS
Animals. Hemizygous IGFBP-2 transgenic mice, as described previously (19) , and nontransgenic controls were used in this study. In experiment 1 (EXP1), 20 IGFBP-2 transgenic mice (10 males and 10 females) and 37 nontransgenic controls (19 males and 18 females) were examined at 72 days of age (50% C57BL/6 and 50% NMRI). In an additional experiment [experiment 2 (EXP2)], 10 male IGFBP-2 transgenic and 10 control mice were examined at 30 days of age (100% C57BL/6). All mice were maintained under standard (nonbarrier) conditions and had free access to a standard diet (breeding diet 1314; Altromin, Lage, Germany). All procedures were done in accordance with the German Law of Animal Protection and approved by the relevant authorities (Landesamt für Landwirtschaft, Lebensmittelsicherheit und Fischerei Mecklenburg-Vorpommern, Germany; LALLF M-V/ TSD/7221.3-2.1-023/09).
Growth and body composition (EXP1).
Body weights were recorded in intervals of 5-7 days until day 42 of age and then on days 63 and 70 of age. Analysis of body composition during growth was carried out with a Lunar PIXImus II Densitometer (GE Medical Systems, Freiburg, Germany) on days 40 and 70 of age. On day 72 of age the animals were euthanized by cervical dislocation, and the M. rectus femoris (RF) and the lower hind leg (LL) were dissected from the carcass and weighed. The composition of the remaining body by water/dry matter, lipid, and ash was analyzed according to standard methods (1) . In brief, bodies were autoclaved at 0.2 MPa and 135°C for 2 h and subsequently dried with repeated stirring in a 105°C oven to a constant weight. Dried bodies were finely ground, and duplicate samples were subjected to ether extraction for fat determination. Ash was determined by incineration in a muffle kiln at 600°C, and protein was determined by difference.
Histology/histochemistry and microscopy (EXP 1). Serial transverse sections (10 m) were cut from the right-side RF at the end of the proximal tendon of origin in a Frigocut 2800 cryostat (Leica, Wetzlar, Germany) at Ϫ20°C and mounted on slides. As described previously (44) , cut sections were stained by NADH-tetrazolium reductase (31) for metabolic fiber types (red, intermediate, and white) or for cytoplasm by eosin (46) and alkaline phosphatase (52) to visualize capillaries. The muscle cross-sectional area (MCSA) of the RF was measured by image analysis (TEMA; Checkvision, Stoevring, Denmark). To determine the total muscle fiber number per cross section, microscopic images were projected on a table, and the fibers were counted over an area of 3.047 mm 2 (ϳ25% of the total MCSA) by a pen counter and extrapolated to the total MCSA. Fiber type distribution, fiber cross-sectional area, and capillary density were determined separately on 100 -150 muscle fibers each in the dark (deep) and bright (superficial) regions of the muscle by image analysis (AMBA; IBSB, Berlin, Germany) that allows the overlay and combination of differently stained serial sections. The cross-sectional areas of the individual fibers and the number of capillaries were recorded in sections stained for eosin/alkaline phosphatase, and the allocation to individual fiber types was done on the basis of NADHtetrazolium reductase-stained sections. The averages of both regions were calculated and given as an estimate for the muscles.
Immunohistochemistry and microscopy (EXP2). Serial transverse frozen sections (8 m) were cut from the right-side RF from 30-dayold males (EXP2) as described above, mounted on poly-L-lysine covered glass slides (Poly-Prep Slides; Sigma Diagnostics, St. Louis, MO), and immediately fixed in Zamboni's fixative (2.0% paraformaldehyde, 15% picric acid, 0.1 M sodium phosphate buffer stock, pH 7.3) for 10 min at room temperature. After washing with PBS (3 ϫ 10 min), slides with tissue sections were incubated with 3% H2O2 for 30 min to block endogenous peroxidase activity and subsequently rinsed in PBS (2 ϫ 5 min). Prior to incubation with the primary antibody, the sections were pretreated with normal goat serum (sc-2043; Santa Cruz Biotechnology, Santa Cruz, CA) for 20 min. The primary rabbit anti-human polyclonal antibody to IGF-I receptor (IGF-IR)␤ (C-20, sc-713, dilution of 1:50; Santa Cruz Biotechnology) or the rabbit anti-human monoclonal antibodies to active caspase-3 (dilution 1:50; BD Biosciences, Heidelberg, Germany) or Ki-67 (clone SP6, ready to use; Biozol, Eching, Germany) were added, and sections were incubated overnight at 4°C. For negative controls, the incubation with primary antibody was omitted or replaced by normal rabbit IgG (sc-2027; Santa Cruz Biotechnology) in a dilution of 1:50. After primary antibody binding, the sections were washed in PBS (5 ϫ 2 min) and incubated with secondary antibody [biotinylated goat antirabbit IgG (H ϩ L), dilution 1:150; Linaris, Wertheim-Bettingen, Germany] for 30 min. After further washings with PBS (2 ϫ 5 min), the tissue sections were incubated for 5 min with a horseradish peroxidase-avidin-biotin complex (Vectastain ABC kit; Vector Laboratories), following the manufacturer's instructions. After final washings with PBS (2 ϫ 5 min), 3,3=-diaminobenzidine (DAB kit; Vector Laboratories) as a chromogen-staining substrate was added to each tissue section for 2 min. Another section was stained with hematoxylin for nuclei (46) , and all sections were mounted in glycerol jelly for evaluation under a light microscope. Digital images were taken from selected sections using the image analysis system Leica DM 2400 (Leica Microsystems, Cambridge, UK). Nuclei were counted in HE sections on four fields spread over the muscle cross section (ϳ17% of the whole area), and Ki-67-positive nuclei within and between myofibers were counted over the whole cross section by image analysis (TEMA) to obtain the number and percentage of proliferating nuclei. Sections stained for active caspase-3 were evaluated for the appearance of apoptotic fibers. Rehfeldt and Walther (45) . RNA was quantified fluorometrically with SYBR Green II (Molecular Probes, Eugene, OR) against RNA from calf liver (Sigma-Aldrich) as a standard according to Oksbjerg et al. (34) . Fluorescence was measured using an Flx-800-I microplate reader (Bio-Tek Instruments, Bad Friedrichshall, Germany). Protein concentration was determined according to Peterson (38) against a bovine serum albumin (Serva) standard. CK activity was measured in supernatants of diluted muscle homogenates at 37°C using a commercial kit (Pointe Scientific, Canton, MI) adapted to microplate application. ICDH and LDH activities were measured using modified assay protocols according to Sigma (http:/www.sigmaaldrich.com/Area_of_Interest/Biochemicals/ Enzyme_Explorer/Key_Resources /Assay_Library.html), as described previously in detail (22) . The optical density in microplate assays was measured using a Spectramax 250 plate reader (Molecular Devices, Sunnyvale, CA).
Biochemical and enzyme analyses (EXP1 and EXP2

SDS-PAGE and Western blot analysis (EXP1 and EXP2
). Muscle tissue of the LLs was scraped from the bone and immediately frozen in liquid nitrogen. Muscular tissues from IGFBP-2 transgenic and nontransgenic male mice on day 30 (EXP2; n ϭ 10/genotype) and day 72 of age (EXP1; n ϭ 5/genotype) were homogenized in extraction buffer, and protein content was quantified using the bicinchoninic acid method, as described previously (2) . Twenty micrograms of protein was separated on 12% SDS-PAGE gels and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Eschborn, Germany). Transfer of the proteins to the membranes was verified by Coomassie blue staining. All signal intensities of pan-specific or phosphospecific antibodies were corrected for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for the respective sample on the respective membrane. Membranes were blocked (5% dry milk and 1% Tween-20 in Tris-buffered saline) and incubated with primary antibodies for 1. Tween-20, membranes were incubated with horseradish peroxidasecoupled goat anti-rabbit IgG (1/2,000, no. 7074; Cell Signaling) for 1 h at room temperature. Finally, membranes were developed on a Kodak Image Station 4000MM (Kodak, Stuttgart, Germany), using an enhanced chemiluminescence detection kit (ECL Advance Western Blotting Detection Kit; GE Healthcare, Freiburg, Germany). Band intensities were quantified using the ImageQuant Software package (GE Healthcare). To estimate the specific activation for distinct signaling molecules, signals derived from phosphospecific antibodies were also normalized for total expression of the respective total protein (phosphospecific/total protein). For that purpose, after detection of phosphorylated residues by phosphospecific antibodies, unstripped PVDF membranes were incubated with pan-specific antibodies, revealing both unphosphorylated and phosphorylated signaling molecules. Results are expressed in percent of nontransgenic controls to compare different blots.
To study the local expression of IGFBP-2 in muscle, proteins were extracted using 1 M acetic acid as described previously (53) . In brief, extracted proteins were quantified, separated by SDS-PAGE, and blotted to PVDF membranes. IGFBPs were detected using the commercial nonradioactive Western ligand blot kit (IBT, Reutlingen, Germany) or with [
125 I]IGF-II, as described previously (19) .
IGF-IR immunoprecipitation and Western blot analysis.
Because the IGF-IR was not detectable in muscle homogenates from mice on day 72 of age, we applied immunoprecipitation to muscle tissues from IGFBP-2 transgenic and nontransgenic male mice from day 72. The samples were homogenized in extraction buffer with 1 mM PMSF. The cell lysate was immunoprecipitated with IGF-IR␤/IR␤ according to the manufacturer's instructions (Cell Signaling) by using Protein G Sepharose 3 Fast Flow (GE Healthcare). The lysates were diluted with 3ϫ SDS sample buffer that contained 187.5 mM Tris·HCl (pH 6.8), 6% (wt/vol) SDS, 30% glycerin, 150 mM DTT, and 0.03% (wt/vol) bromophenol blue. Protein content was then quantified using the bicinchoninic acid method (2) . Equivalent amounts of protein were separated on 12% SDS-PAGE gels, transferred to PVDF membranes, and incubated with an antibody against the phosphorylation site of IGF-IR␤/IR␤ (on Tyr 1150 / 1151 or Tyr 1135 / 1136 , rabbit mAb no. 3024) and an antibody against total IGF-IR␤/IR␤, as described above.
Statistical analysis. Data were subjected to analyses of variance using the mixed model of SAS (SAS System for Windows Release 9.1; SAS Institute, Cary, NC), including genotype, sex, and their interaction as fixed factors and the dam as random factor. Data given in the tables and figures are least squares means Ϯ SE. In the case of significant interactions of genotype and sex, significance of differences between least squares means was tested post hoc using Student's t-test (P Ͻ 0.05). Data from the analysis of signal transduction were expressed as means Ϯ SE (n ϭ 10), and differences were tested by the two-sided Student t-test.
RESULTS
Growth and body composition. Transgenic mice and their nontransgenic littermates differed in postnatal growth development that has been followed up from birth to day 70 of age ( Fig. 1A) . At birth and day 5 of age, body weight tended to be lower in transgenic mice (P ϭ 0.10), whereas no differences were apparent afterward until 3 wk of age. Starting on day 21 of age, the body weight of the transgenic mice was significantly reduced by 6 -8% of the wild-type controls on average. On the final day of life (day 72) the effect of the IGFBP-2 transgene was revealed to be greater in males (10%) than in females (4%), as underlined by a significant genotype by sex interaction (P Ͻ 0.01). Measurements on the composition of total mouse bodies by tissues using densitometry on days 42 and 70 of age (Table 1) showed that bone area and bone mineral content were lower, but bone mineral density remained unchanged. Fat proportion was significantly increased by 1.2% units on average (P Ͻ 0.001; Fig. 1B ), which means that lean percentage was correspondingly decreased. Data on body composition obtained by chemical analysis also showed that the bodies of transgenic mice contained a higher percentage of fat (ϩ1.9% units on average) and, conversely, lower percentages of moisture and protein, with ash percentage being equal with nontransgenic mice. The differences in body fat and moisture were more pronounced in males than in females, as indicated by significant interactions of genotype and sex. Differences between the genotypes were significant from day 21 of age onward (P Ͻ 0.05). B: %body fat measured in 42-and 70-day-old mice by densitometry from total body imaging (PIXImus). On days 42 and 70 of age there were significant effects of genotype (P Ͻ 0.001). Effects of sex (P Ͻ 0.01) and interaction of genotype and sex (P Ͻ 0.10) were apparent only on day 70. C: weights of the M. rectus femoris (RF) and of the lower leg (LL) recorded on day 72 of age. There were significant effects of the genotype (P Ͻ 0.0001), sex (P Ͻ 0.0001), and interaction of genotype and sex (P Ͻ 0.001). In B and C, least squares means and SE are represented by columns and error bars, respectively. Different letters indicate significant differences (P Ͻ 0.05).
Muscle weights, DNA, RNA, protein concentrations, and CK activity. The weights of the RF muscle and the LL were significantly reduced by 14% on average in transgenic mice on day 72 of age (EXP 1; Fig. 1C ), which clearly exceeded the reduction in overall body weight, leading to a decrease in relative RF weight (Table 2) . Likewise, the RF muscle crosssectional area was reduced by 10%. For the above-mentioned muscle traits, the effect of the transgene was more pronounced in males than in females (for genotype by sex interaction, P Ͻ 0.05 to P Ͻ 0.0001). Consistently, the RF muscle tissue contained lower total amounts of DNA (92%), RNA (81%), and protein (85%) in transgenic compared with control mice ( Table 2 ). The concentration of DNA was higher in transgenic muscle, whereas the concentrations of RNA and protein did not differ between the genotypes. Correspondingly, the ratios of DNA/RNA and DNA/protein were clearly greater in transgenic compared with nontransgenic muscles, whereas protein/RNA tended to be increased. Significant interactions revealed that the effects on total RNA and protein contents and on DNA/RNA ratio were more pronounced in males than in females. Analyses of the results of male mice on day 30 of age showed that the absolute (Ϫ13%) and relative weights of RF muscle were already reduced in young transgenic mice (EXP2; Table 3 ). Similar to day 72, total DNA and RNA were lower in transgenic muscles, whereas total protein was not yet decreased, and likewise, DNA concentration and DNA/protein ratios were still unchanged. However, DNA/RNA and protein/RNA ratios were greater on day 30, as observed on day 72 of age. Like protein concentration, CK activity, which can also be taken as a marker of differentiation as reflecting the proportion of muscle fiber protein, was not affected by the IGFBP-2 transgene on days 30 and 72 of age (data not shown).
Myofiber number and size and capillary density. The reduction in muscle mass in transgenic mice was not related to decreases in the number of myofibers but resulted mainly from smaller (Ϫ12% on average) fiber cross-sectional areas (EXP1; Fig. 2, A and B) , with all types of fibers, such as red, intermediate, and white, being affected (data not shown). Like for muscle weight and size, the effects of the transgene on fiber size were more pronounced in males than in females, as revealed by significant interactions. To elucidate whether the overexpression of IGFBP-2 would affect muscular vascularization, capillary density has been analyzed. The average number of capillaries per muscle fiber was lower, by 18%, on average (1.50 Ϯ 0.12 vs. 1.83 Ϯ 0.14; Fig. 2C ) in transgenic compared with nontransgenic mice, with all fiber types being affected. In this case, no sex-specific response to the overexpression of IGFBP-2 was observed. However, the muscle fiber area per capillary as a measurement of the fiber area supplied by one capillary was not affected by the genotype (data not shown).
Metabolic fiber type distribution and enzyme activities. The RF muscle is a mixed muscle that consists predominantly of white glycolytic myofibers containing few mitochondria (Fig. 3) . The estimates for fiber type composition on day 72 of age (EXP1) were ϳ55% white, with almost equal proportions (25%) of red and intermediate fibers, with females exhibiting more oxidative features in terms of fiber type composition. On average, no differences were apparent between transgenic and nontransgenic mice. However, significant genotype by sex interactions (P Ͻ 0.01) revealed an increase in the percentage of white fibers at the expense of intermediate fibers by 4.4% units in male carriers of the IGFBP-2 construct, which is indicative of a shift to the glycolytic muscle metabolism. The measurement results of ICDH and LDH activities as markers of the oxidative and anaerobic/glycolytic muscle metabolism, respectively, were consistent with the shift to the glycolytic pathway of energy generation in terms of fiber type composition. Whereas the ICDH activity remained unchanged, the LDH activity was increased by 8 -10% compared with the nontransgenic muscle, which was significant only in males (Table 2 ). On day 30 of age, a shift to glycolytic muscle metabolism in terms of LDH activity was not yet apparent (EXP2; Table 3) .
Immunohistochemistry of proliferation, apoptosis, and IGF-IR expression in muscle tissue. The abundance of proliferating nuclei within the cross section of the RF muscle was examined in young males on day 30 of age (EXP2) on the basis of the proliferation-related Ki-67 antigen (Fig. 4) . Although numerically less in transgenic muscle, the total number of nuclei in the RF cross section stained by hematoxyline did not differ significantly by genotype (Table 3) . However, the number of proliferating nuclei in RF cross section was lower in transgenic compared with control mice (134 Ϯ 39 vs. 375 Ϯ 59, P ϭ 0.07). This resulted in lower percentages of Ki-67- Fig. 2 . Average fiber cross-sectional area (FCSA), total fiber number, and capillaries/fiber in RF in IGFBP-2 tg and control mice at 72 days of age. Least squares means and SE are represented by columns and error bars, respectively. Columns bearing a letter in common are not significantly different (P Ͼ 0.05). There were significant effects of genotype (P Ͻ 0.01), sex (P Ͻ 0.0001), and interaction of genotype and sex (P Ͻ 0.05) for FCSA. For the number of capillaries per fiber, the effects of genotype (P Ͻ 0.05) and sex (P Ͻ 0.01) were significant. positive nuclei of both all nuclei detected together in the cross section and those nuclei located separately within myofibers (Table 3 ). There were no clear signs of apoptosis related to the expression of the active caspase-3 in muscle cross sections from controls and transgenic mice, except that a few positive cells were located in connective tissue in some of the sections (data not shown). The IGF-IR␤/IGF-IR precursor protein was detected in muscle sections from all animals (Fig. 5A) . Interestingly, IGF-IR␤/IGF-IR precursor immunoreactivity was found with higher abundance in red and intermediate oxidative myofibers but with low intensity in white glycolytic myofibers. Intense immunostaining was observed around the sarcolemma, in the nuclei, and spot-like in the cytoplasm. At 72 days of age, we observed only very weak immunoreactivity for the IGF-IR (Fig. 5C ).
Transgene expression in muscle tissue. To establish transgenic expression of IGFBP-2 in muscle tissue from 10-wk-old male mice (EXP1) and to further investigate expression of other IGFBPs in this tissue, Western ligand blotting was performed, which detects transgenic IGFBP-2 but also other IGFBPs characterized by high affinity for the IGFs. Western ligand blotting revealed a band in extracts from IGFBP-2 transgenic mice but only faint signals in protein extracts from nontransgenic littermates (Fig. 6) . The molecular weight corresponded to ϳ32 kDa, which identifies IGFBP-2 beyond other IGFBPs. No other IGF-binding activity was identified in transgenic or nontransgenic mice. Signals from Coomassie-stained PVDF membranes after blotting indicate equal loading of the gels, proper transfer, and comparable quality of the protein extracts used in the analysis. Analysis of signal transduction. In EXP1 and/or EXP2 the expression and activation of selected signal molecules was studied in male mice, where the overexpression of IGFBP-2 had stronger inhibitory effects on growth compared with females. In IGFBP-2 transgenic mice of both age groups, higher levels of phosphorylated Akt at Ser 473 were present if compared with nontransgenic controls (by 25 and 66% on days 30 and 72, respectively; Fig. 7 ), whereas Akt phosporylated at Thr 308 could not be detected. The specific activation of p44/42 MAPK on day 30 was similar in transgenic and nontransgenic mice, whereas activation on day 72 was slightly reduced (by 18%; Fig. 8 ). Specific activation of p38 MAPK remained unaffected by the genotype in both age groups (day 30: transgenic 84 Ϯ 54%, controls 100 Ϯ 86%, P ϭ 0.626; day 72: transgenic 184 Ϯ 78%, controls 100 Ϯ 79%, P ϭ 0.134). JNK (transgenic 89 Ϯ 7%, controls 100 Ϯ 9%, P ϭ 0.068) and PDK1 (transgenic 141 Ϯ 59%, controls 100 Ϯ 28%, P ϭ 0.500) measured on day 72 were also unaffected by the genotype. Specific activation of the IGF-IR␤/IR␤ could be detected only in muscles from 30-day-old mice with similar expression levels in transgenic and nontransgenic mice (Fig. 9) . The presence of IGF-IR in muscle tissue from 72-day-old mice could be confirmed on a low level by Western immunoblot analysis of immunoprecipitates but not of tissue homogenates (data not shown). However, the faint bands did not allow reliable quantification of IGF-IR activation at this time point. The MyoD expression of younger mice (day 30) was similar in transgenic and control animals, whereas adult transgenic mice (day 72) tended to express less MyoD (by 18%, P ϭ 0.095) compared with nontransgenic mice (Fig. 10) .
DISCUSSION
The acquisition and maintenance of muscle mass represents an important issue of current economy and medicine. On the one hand, factors affecting muscle accretion are of central interest to farm animal biology; on the other hand, maintenance of muscle mass represents one aspect of functional ability in modern civilizations not only with respect to the Western lifestyle but also with respect to the aging population. As a novel factor negatively interfering with muscle accretion, IGFBP-2 deserves specific attention since overexpression of IGFBP-2 in transgenic mice indicated muscular tissue as the main target tissue of IGFBP-2. In IGFBP-2, transgenic mouse carcass weight displayed the strongest weight reduction compared with all other tissues (21) . In human patients, higher serum IGFBP-2 concentrations were negatively associated with muscle strength (55). Also, in chicken (26) and pigs (5, 57) IGFBP-2 has been discussed as an effector of muscle accretion. To define the physiological basis of the negative effects of IGFBP-2 on carcass weight, we have now performed this study in the IGFBP-2 transgenic mouse model, focusing on muscle and fat accretion and cellular aspects of muscle fiber composition and metabolism.
Effects of elevated IGFBP-2 on body growth have been observed not before day 21 of postnatal life in the present study, which is consistent with results reported previously (19, 21) . Overexpression of IGFBP-2 in transgenic mice does not affect food consumption that is normal in IGFBP-2 transgenic mice, as demonstrated recently (8) . Instead, we have reason to assume growth inhibitory effects of IGFBP-2 since bone lengths were reduced (11) and, as we show here, fat mass was increased in our IGFBP-2 transgenic mouse model. At 10 wk of age, body weight was slightly lower (Ϫ7%) in IGFBP-2 transgenic mice compared with nontransgenic littermates. At the same time, the weights of isolated muscles were reduced by 14% in IGFBP-2 transgenic mice, indicating overproportionate weight reductions in skeletal muscle tissue, which is also in perfect agreement with previous results obtained for carcass weight (21) . Similar reductions in the absolute and relative RF weights were already apparent on day 30 of age in male transgenic mice, indicating an early inhibition of skeletal muscle growth. Although muscle accretion was impaired in IGFBP-2 transgenic mice, chemical analysis revealed a massive increase of fat mass (ϩ29% relative to controls) at 72 days of age. The higher body fat percentage by densitometry and chemical analyses found in this study and the slight increases in abdominal fat mass at 5 and 15 wk of age (19) seem to be age-dependent since in 36-wk-old mice overexpression of IGFBP-2 resulted in a block of age-related fat accumulation (58) . Definitely the age-dependent effects of IGFBP-2 and particularly the mechanisms of differential fat accretion deserve further investigation.
Higher levels of IGFBP-2 in our transgenic mouse model have been shown previously in the circulation but also in various tissues and organs, including skeletal muscle (21) . Results of the present study, where we detected increased local expression of IGFBP-2 in muscle tissue extracts from 72-dayold male mice, confirm previous reports but at the same time reveal no alteration of other IGFBPs in muscle tissue, since no other IGFBPs were identified. As demonstrated earlier, overexpression of IGFBP-2 does not affect serum concentrations of IGF-I or -II (19 -21) . Hence, the effects of IGFBP-2 on skeletal muscles can be due to endocrine or paracrine/autocrine mechanisms in that tissue. Surprisingly, myofiber number was similar in IGFBP-2 transgenic and nontransgenic mice despite Fig. 7 . Specific activation of Akt phosphorylated on Ser 473 in skeletal muscle tissues from 30-(left) and 72-day-old (right) IGFBP-2 tg and control mice represented by the ratios of phosphorylated vs. total Akt. Equal amounts of protein were loaded on SDS-PAGE gels and blotted onto PVDF membranes. Membranes were stained by Coomassie blue to verify proper transfer of the protein samples and incubated with antibodies directed against Akt phosphorylated at Ser 473 or GAPDH. Total expression of Akt was detected by antiserum, which also recognizes unphosphorylated Akt. The results are given as means Ϯ SE; n ϭ 10 in total. Statistical significance was fixed by the 2-sided Student t-test in 30-day-old (P ϭ 0.035) and in 72-day-old mice (P ϭ 0.004). smaller muscles in the transgenic group. Muscle fiber formation, which occurs during prenatal and early postnatal myogenesis, is highly dependent on IGF-I and IGF-II (14) . Since the number of muscle fibers in mice is determined early in life (43) , and IGFBP-2 did not reveal overall effects on body weight up to 3 wk of age, it might be concluded that IGFBP-2 either has no effect on myogenesis or that IGFBP-2 is not overexpressed in the transgenic mice during the early growth phase. However, as demonstrated earlier, both endogenous and transgenic IGFBP-2 are in fact expressed in the perinatal growth period (19) . Since endogenous IGFBP-2 expression was comparably high in both genetic groups, it may well be that endogenous IGFBP-2 also masks the effects of transgenic IGFBP-2 as discussed for the lack of effect on body weight in the perinatal period (19) . In the postnatal growth period, muscle growth is achieved mainly by an increase in muscle fiber size but not by an increase in muscle fiber number (42, 43) . Myofiber growth in turn is mediated through the proliferative activity of satellite cells and muscle-specific protein accretion (29, 30, 49) . Immunohistochemical analysis of the proliferation-related Ki-67 antigen on day 30 of age revealed that myogenic proliferation, in particular satellite cell activity, was reduced considerably (by ϳ40%) in transgenic muscle, whereas signs of apoptosis were hardly apparent in muscles of both genotypes. However, this was not associated with changes in MyoD expression, which is known to be expressed not only in activated satellite cells but also by their differentiating progeny (61) . Actually, unchanged MyoD expression and CK activity suggest that the status of myogenic differentiation was not influenced by the IGFBP-2 transgene in young mice. In the older mice the tendency for less MyoD expression may be indicative of a lower abundance of satellite cells in the transgenic mice. Histological and biochemical analyses of RF muscle from IGFBP-2 transgenic mice (day 72 of age) revealed smaller fiber cross-sectional areas and lower total DNA, RNA, and protein contents when compared with wild-type littermates. Considering myonuclei and myofibrillar protein as the main constituents of skeletal muscle, inhibition of postnatal muscle growth by IGFBP-2 functions at the level of both myogenic proliferation and myofiber protein accretion. The latter is more affected and realized mainly through reduced transcriptional activity of protein synthesis and/or lower RNA stability, as indicated by higher DNA/RNA ratio in transgenic muscle. As a consequence, myofibers grow slower in size during postnatal growth. From in vitro studies, growth-stimulating effects of IGF-I in terms of proliferation and protein accumulation on murine, rodent, and other mammalian myoblasts are well recognized (3, 9, 14, 39) . There is also evidence that IGF can mediate skeletal muscle hypertrophy in a fashion independent of myogenic proliferation (40) . To specify the mechanisms active in IGFBP-2 transgenic mice, we have screened central signaling pathways in muscle extracts from male mice at 30 days and at 72 days of age. Although we were able to identify slight reductions of p44/42 MAPK phosphorylation, particularly at 72 days of age, we found no specific effect of p38 MAPK, JNK, or PDK1 activation. Interestingly, inhibition of IGF-I-dependent activation of p44/42 MAPK blocked IGF-Iinduced hypertrophy in rat muscles (17) . However, partial inactivation of p44/42 MAPK by IGFBP-2 has also been demonstrated by an integrin-dependent and IGF-independent mechanism in tumor cells that do not express functional IGF-I receptors (48) . Surprisingly, activation of Akt on Ser 473 was increased massively in muscle tissue from 30-and 72-day-old male IGFBP-2 transgenic mice. Interestingly, the protein/RNA ratio was also increased on days 30 and 72 of age, which may be indicative of intensified protein synthesis at the level of translation and is therefore consistent with Akt activation. This specific Akt activation was unexpected since the activation of Akt results in muscle hypertrophy (15) . Activation of Akt on Ser 473 is due to the exclusive activity of TOR complex 2 (TORC2) (identical to PDK2) (6) . To date, activation of TORC2, which is thought to occur by growth factors or insulin, has been demonstrated only for insulin (62) but might also occur by integrin-dependent mechanisms since Rictor from the TORC2 was found to control Akt Ser 473 activation if complexed with integrin linked kinase (28) . Importantly, specific activation of Akt on Ser 473 by IGFBP-2 has been observed in vivo, and serum levels of IGFBP-2 have been discussed as novel biomarkers of Akt activation (58) . Thus the strong interrelationship between IGFBP-2 and Akt activation might be present not only in malignant conditions but also in nonmalignant growth regulation. It may well be that this specific activation may explain other conditional effects of IGFBP-2 discussed, e.g., in malignant systems (58) . Several studies have provided evidence for integrin-mediated effects of IGFBP-2 (10), and it has been shown to decrease activation of focal adhesion kinase in vitro (48) . Molecular basis of an interaction of IGFBP-2 with integrins is the RGD sequence present in IGFBP-2. Taken together, we hypothesize that the inhibitory effects of IGFBP-2 on myofiber growth in vivo are realized mainly through an impairment of myogenic proliferation and transcriptional processes (less proliferating myogenic cells, less DNA, and greater DNA/RNA ratio, which correlates with decreased MAPK activation) and not through an impairment of protein synthesis, which would hardly correlate with higher Akt activation and increased protein/RNA ratio. A putative impairment of protein synthesis by the lack of IGF-I might also be masked or overcompensated through the action of hormones and growth factors other than IGFs. However, this requires more detailed research.
The distribution of fiber types in skeletal muscle differentiated as red, intermediate, and white fibers and the activities of LDH or ICDH are characteristic of the predominant metabolic pathway providing the energy for their contraction. The M. rectus femoris examined in this study is highly oxidative at birth and develops predominantly glycolytic features during postnatal growth through differentiation into fiber types of different metabolic features (43) . This fiber type conversion from red via intermediate to white fibers stops at approximately 6 -7 wk of age together with the exponential growth phase. The greater relative abundance of white glycolytic muscle fibers at the expense of intermediate fibers and the higher activity of LDH in muscles of IGFBP-2 transgenic mice are indicative of a slight shift to the anaerobic/glycolytic metabolic pathway of energy generation. This may be associated with lower metabolic rate and degree of fatty acid oxidation and is therefore a putative explanation for the higher fat accumulation in IGFBP-2 transgenic mice. Because only the number of capillaries per fiber but not the number of capillaries per myofiber area was different between the genotypes, the changes in fiber type distribution seem not to be related to a lower oxygen and substrate supply, at least in terms of the capillaries as the morphological prerequisites. We have shown in this study that the IGF-IR is more intensely expressed in red and intermediate oxidative than in white glycolytic myofibers. To our knowledge, fiber type-specific expression of the IGF-IR has not shown before, but it is in agreement with the result that red muscles exhibited a higher tyrosine kinase activity than white rat muscles (64) . The observed distribution pattern is consistent with previous work (54) describing the IGF-IR to be localized around the Z-bands of the myofibrils, the sarcolemma, and mitochondrial and nuclear membranes in human skeletal myofibers. In whole tissue lysates, an effect of elevated IGFBP-2 expression in transgenic mice on the activation of IGF-IR was not measurable on day 30 of age, where a shift to glycolytic muscle metabolism was not yet apparent. The observed very weak immunoreactivity for the IGF-IR in tissue sections and its very weak appearance in Western blot analysis after immunoprecipitation, which did not allow for reliable quantification at 72 days of age, are consistent with the decline in the abundance of the IGF-IR in skeletal muscles with increasing age (37) , which may be a feature of transition from exponential somatic growth to slower growth phases with progressing age. To our knowledge, there is only one study (35) where the activation of the IGF-IR in skeletal muscle tissue of mice at 10 wk of age has been quantified, but the strains of mice (SIS2 and Wt, FVB) were different from those used in our study. It also remains to be determined whether the effect of IGFBP-2 on muscle fiber types is related to higher fat accumulation. Certainly, the results of this study are another indication of the importance of IGFBP-2 and particularly suggest a role (58) in carbohydrate and lipid metabolism. The physiological relevance of these questions for the aging generation characterized by higher fat mass and lower muscle mass has outmost dimensions. Since IGFBP-2 is a marker of functional disability in elder male patients (55), the IGFBP-2 transgenic mouse model has the potential of an in vivo relevant model for muscle maintenance metabolism and fat accumulation.
Overall, the effects of IGFBP-2 were more pronounced in males than in females. IGFBP-2 has been discussed previously as a novel regulator of sex differences in bone growth (7) . The physiological basis of sex-specific effects in muscular tissue cannot be attributed to IGF-dependent or -independent mechanisms by the results of the present study. Nevertheless, during exponential growth, male mice exhibit higher IGF-I plasma levels compared with female mice least after 1 and until 10 wk of age (23) , which might be a potential target of IGFBP-2 actions in vivo. Also in rats, IGF-I levels were found to be higher in males than in females at 80 days of age (16) .
In conclusion, IGFBP-2 overexpression in postnatal mice until 10 wk of age leads to growth retardation and increased accumulation of body fat. IGFBP-2 is an effective inhibitor of absolute and relative skeletal muscle growth resulting from reduced myofiber hypertrophy due to reduced myogenic (satellite cell) proliferation and protein accretion with adequately reduced vascularization. Attenuated myofiber growth seems not to result from an impaired Akt-mediated protein synthesis but might be related in part to reduced MAPK activation and impairment of transcriptional processes. In addition, IGFBP-2 overexpression causes a slight shift toward anaerobic/glycolytic muscle metabolism in adult mice. A clear sexual dimorphism is apparent in that the effects of high IGFBP-2 expression are more pronounced in males than in females. The molecular mechanisms and the age-dependent sequences by which IGFBP-2 affects skeletal muscle growth and fat accu-mulation as well as the marked activation of Akt on Ser 473 in muscle tissue require further research.
